Journal article icon

Journal article

Once- versus twice-daily abacavir and lamivudine in African children: the randomised controlled ARROW Trial

Abstract:

Background: Antiretroviral therapy (ART) adherence is critical for successful HIV treatment outcomes. Once-daily dosing could improve adherence. Plasma concentrations of once-daily vs twice-daily abacavir + lamivudine are bioequivalent in children, but no randomized trial has compared virological outcomes.
Methods: Children taking abacavir + lamivudine-containing first-line regimens twice daily for more than 36 weeks in the ARROW trial (NCT02028676, ISRCTN24791884) were randomized to co...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Publisher's version

Actions


Access Document


Files:
Publisher copy:
10.1097/QAD.0000000000001116

Authors


Musiime, V More by this author
Kasirye, P More by this author
Naidoo-James, B More by this author
Nahirya-Ntege, P More by this author
Expand authors...
UK Department for International Development More from this funder
Publisher:
Lippincott, Williams and Wilkins Publisher's website
Journal:
AIDS Journal website
Publication date:
2016-07-17
DOI:
EISSN:
1473-5571
ISSN:
0269-9370
URN:
uuid:e90f7c66-1701-43bb-9f99-df9023a9d366
Source identifiers:
612732
Local pid:
pubs:612732

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP